Allergic asthma is a chronic pulmonary disorder characterized by reversible episodes of airway obstruction, pronounced airway hyperresponsiveness (AHR), peribronchial inflammation, and airway remodeling. 1 Macrophages are the most abundant inflammatory cells in the airways, where they produce copious amounts of cytokines, such as IL-1b, IL-13, and IL-17, to exacerbate asthma pathologic processes. [2] [3] [4] Macrophages can be activated by IFN-g or LPS to manifest a classically activated phenotype (M1) 5 or by IL-4 and IL-13 to display an alternatively activated phenotype (M2). 6 Importantly, airways in patients with allergic asthma are predominantly infiltrated by M2 macrophages during the course of disease development and progression, 7 and studies in animals revealed that M2 macrophages might represent a novel target for the prevention Tfec: Transcription factor EC WT: Wild-type and treatment of asthma. 8, 9 Indeed, M2 macrophages produce many factors, such as IL-13, Ccl17, Ccl22, eotaxin, Ym1, and found in inflammatory zone 1 (Fizz1), contributing to airway inflammatory and remodeling responses during the course of asthma development. 3, [10] [11] [12] C/EBP homologous protein (Chop; also known as Gadd153 or Chop10) is a marker of endoplasmic reticulum (ER) stress activated by eukaryotic initiation factor 2a (eIF2a) phosphorylation and activating transcription factor 4 (Atf4) upregulation. 13 Recently, aberrant CHOP expression along with ER stress has been reported in asthmatic patients and animal models of asthma [14] [15] [16] ; however, the significance of Chop in asthma pathogenesis remains unclear. There is feasible evidence that ER stress can modulate the activation of M2 macrophages, 17 and we also noted that macrophages derived from induced sputum samples of asthmatic patients manifest a significant CHOP upregulation. Thus we hypothesized that CHOP mediates the generation of M2 macrophages to facilitate the pathologic changes associated with asthma development. To address this hypothesis, an ovalbumin (OVA)-induced allergic airway inflammation model was used to assess the effect of Chop deficiency on disease development. Remarkably, the loss of Chop significantly attenuated OVA-induced inflammation along with a marked reduction of M2 macrophage infiltration in the lungs. Mechanistic studies have revealed that Chop regulates signal transducer and activator of transcription 6 (STAT6) phosphorylation, thereby enhancing expression of mouse transcription factor EC (Tfec), which then transcribes IL-4 receptor a (IL-4Ra) expression to promote M2 programming in macrophages. Together, our data provide novel insights into the role of ER stress in asthma pathogenesis.
METHODS
Further details can be found in the Methods section in this article's Online Repository at www.jacionline.org.
Animals
Chop knockout (Chop 2/2 ) mice were purchased from the Jackson Laboratory (Bar Harbor, Me). Wild-type (WT) mice were obtained from the Animal Experimental Center of Hubei Province (Wuhan, China). All animals were housed in a specific pathogen-free animal facility at the Tongji Medical College under a 12-hour light/dark photocycle with food and water available ad libitum. All experimental procedures were approved by the Animal Care and Use Committee of the Tongji Hospital of Huazhong University of Science and Technology.
Model for OVA-induced allergic airway inflammation in mice
Asthma was induced in WT and Chop 2/2 mice (8-10 weeks old), as previously described, with minor modifications. 18, 19 Briefly, the mice were sensitized by using intraperitoneal injection of 100 mg of OVA (grade V) emulsified in 1 mg of aluminum hydroxide gel (Thermo Scientific, Rockford, Ill) in a total volume of 200 mL on days 0, 7, and 14, respectively. Mice injected with an equal volume of saline served as control animals. The sensitized mice were anesthetized with diethyl ether and intranasally challenged with 50 mL of OVA (20 mg/mL) or saline for 7 consecutive days.
Macrophage depletion and macrophage adoptive transfer studies
Clodronate liposomes (40 mL) were administered for 2 consecutive days through intratracheal injection 7 days before OVA induction, and asthma severity was assessed after 7 consecutive days of OVA challenge. The adoptive transfer studies were conducted, as previously described. 20 Peritoneal macrophages derived from WT or Chop 2/2 mice were stimulated with IL-4 (10 ng/mL) or PBS for 12 hours and then administered by means of intratracheal injection into the lungs of clodronate liposome-treated WT and Chop 2/2 mice at a density of 1 3 10 6 cells/mouse (50 mL) 1 day before OVA challenge, as described above. The animals were then killed for further analysis.
Statistical analysis
All data are presented as means 6 SEMs, and all in vitro studies were replicated a minimum of 3 times. Statistical analyses of the data were conducted with GraphPad Prism 5 software (GraphPad Software, San Diego, Calif) and standard 1-way ANOVA or the Dunnett multiple comparison test when appropriate. For all statistical comparisons, a P value of less than .05 was considered statistically significant.
RESULTS

Asthmatic patients and mice exhibit aberrant Chop expression and ER stress
We first examined the expression of CHOP in induced sputum samples obtained from asthmatic patients. CHOP was expressed at low levels in sputum derived from control subjects, whereas higher levels of CHOP were detected in induced sputum samples originating from asthmatic patients (Fig 1, A) . We also examined the expression of binding immunoglobulin protein (BIP), another marker of ER stress. Similar to CHOP, BIP was expressed at significantly higher levels in asthmatic patients compared with control subjects (Fig 1, B) .
To explore the function of Chop in relation to allergic airway inflammation, we used a mouse model induced by OVA peptides. A 2-fold increase in Chop expression was observed in allergic mice compared with control mice (Fig 1, C) . Consistently, levels of phosphorylated eIF2a (Fig 1, D) , Atf4 (Fig 1, E) , and Bip (Fig 1, F) as additional markers of ER stress were also significantly increased in allergic mice compared with control mice. Collectively, these data support the notion that the pathogenesis of asthma is associated with ER stress.
Chop deficiency attenuates OVA-induced allergic airway inflammation in mice Because asthmatic patients and mice manifested altered expression of ER stress markers, we next sought to determine the effect of ER stress on the development of asthma by using Chopdeficient mice. As expected, severe inflammatory responses were observed in WT mice after 7 days of repeated OVA challenges, as demonstrated by the infiltration of inflammatory cells into the peribronchiolar and perivascular connective tissues. However, Chop 2/2 mice exhibited markedly lower inflammatory scores, indicating that the loss of Chop significantly attenuated OVA-induced inflammatory responses (1.74 6 0.20 vs 2.96 6 0.30, P < .01; Fig 2, A and D) . Next, we examined mucus production by using periodic acid-Schiff staining. Severe goblet cell hyperplasia and mucus hypersecretion within the bronchi were observed in OVAchallenged WT mice, and these defects were significantly less severe in OVA-challenged Chop 2/2 mice (2.32 6 0.29 vs 1.31 6 0.19, P < .05; Fig 2, B and E) . Because the thickening of the airway wall is a characteristic feature of airway remodeling, we further assessed airway peribronchial collagen deposition using Masson trichrome staining. Similarly, repeated exposure to OVA for 7 consecutive days increased peribronchial collagen deposition in WT mice compared with that seen in saline-treated control mice. However, loss of Chop dramatically attenuated OVA-induced peribronchial collagen deposition as well compared with that in WT mice (0.14 6 0.02 vs 0.24 6 0.02, P < .001; Fig 2, C and F) .
Next, we compared the number and subtype of inflammatory cells in the bronchoalveolar lavage fluid (BALF) group. Consistent with the above-mentioned observations, the total number of inflammatory cells in BALF derived from Chop 2/2 mice was significantly reduced compared with that in WT mice (7.17 6 0.55 vs 11.91 6 1.05 3 10 5 /mL, P < .01; Fig 3, A) . Specifically, BALF derived from OVA-challenged Chop and WT mice (0.48 6 0.10 vs 0.48 6 0.09 3 10 5 /mL, P > .05; Fig 3, E) . In addition, we compared the cytokine profiles of BALF samples obtained from OVA-challenged Chop 2/2 and WT mice using an ELISA. BALF samples derived from Chop 2/2 mice were characterized by the significantly attenuated levels of IL-4, IL-5, IL-13, TGF-b1, and Ccl17 (Fig 3, F-J) compared with WT mice. However, no significant differences in IFN-g, IL-1b, and IL-10 levels were observed (Fig 3, K-M) . Collectively, these FIG 1. Analysis of ER stress markers in asthmatic patients and OVA-challenged mice. A, CHOP expression in induced sputum samples from asthmatic patients (AP; n 5 6) and healthy subjects (HS; n 5 6). B, BIP expression in induced sputum from AP and HS. C-F, Expression of Chop (Fig 1, C) , phosphorylated eIF2a (Fig 1, D) , Atf4 (Fig 1, E) , and Bip (Fig 1, F) in the lungs of mice after OVA challenge. Data were collected from 6 mice in each study group. *P < .05, **P < .01, and ***P < .001. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
results suggest that Chop deficiency represses production of T H 2 cytokines by inflammatory cells.
To further evaluate the effect of Chop deficiency on asthma pathogenesis, we examined AHR by assessing lung resistance (Rn) in response to increasing concentrations of acetylcholine in mechanically ventilated mice. As expected, OVA-challenged WT mice had AHR, as demonstrated by the increase in Rn values induced by acetylcholine compared with those in the saline-treated control mice. Notably, OVA-challenged Chop 2/2 mice exhibited a marked reduction in Rn values in response to acetylcholine compared with OVA-challenged WT mice (25 mg/mL: 2.57 6 0.25 vs 4.56 6 0.33 cm H 2 O s/mL, P < .001; 50 mg/mL: 3.83 6 0.27 vs 7.69 6 0.77 cm H 2 O s/mL, P < .001; Fig 3, N) . Together, these data demonstrate that loss of Chop provides protection for mice against OVA-induced allergic airway inflammation.
Chop deficiency impairs M2 macrophage induction
To dissect the mechanisms by which Chop deficiency represses OVA-induced allergic inflammation and airway responsiveness, we determined the specific cell types associated with aberrant CHOP expression in BALF samples. Chop was predominantly localized within the F4/80-positive macrophages in OVA-challenged WT mice compared with saline-treated control mice (Fig 4, A) , and similar results were observed with analysis of lung sections (see Fig E1 in this article's Online Repository at www.jacionline.org).
Macrophages are the most abundant type of inflammatory cells in the airway. In particular, polarized M2 macrophages produce copious amount of cytokines in the airway to exacerbate asthma progression. 3 Based on these findings, we hypothesized that Chop exacerbates OVA-induced allergic inflammatory responses and AHR by enhancing M2 programming in macrophages. Indeed, flow cytometric analysis revealed a significantly lower number of M2 macrophages in OVAchallenged Chop 2/2 mice, as manifested by CD206 expression (2.18% 6 0.31% vs 6.79% 6 0.90%, P < .05; Fig 4, B) . Furthermore, Western blot analysis of lung samples derived from OVA-challenged WT mice exhibited a 6-fold increase in levels of the M2 marker arginase-1 compared with those in saline-treated control mice (Fig 4, C) . However, arginase-1 expression was reduced by 1-fold in Chop 2/2 mice after similar (Fig 2, D) , mucus production (Fig 2, E) , and fibrosis ratio (Fig 2, F) . Images were captured with a microscope at a magnification of 3200. Data were collected from 4 to 6 mice in each study group. *P < .05, **P < .01, and ***P < .001.
procedures for OVA challenges (Fig 4, C) . Similar results were observed by using RT-PCR analysis of 4 additional M2 markers: Fizz1, Ym1 (Fig 4, D and E), CD206, and Ccl17 (see Fig E2, A and B, in this article's Online Repository at www.jacionline. org). Unlike its effect on M2 macrophages, Chop deficiency did not seem to affect M1 macrophage induction because we failed to detect perceptible differences in the number of CD11c 1 F4/ 80 1 macrophages after OVA challenges (see Fig E2, C) . Together, these data suggest that the loss of Chop protects mice from OVAinduced allergic airway inflammation by inhibiting polarization of M2 macrophages in the airways.
M2 macrophages are required for Chop deficiencymediated protection against allergic airway inflammation
To investigate whether the protective effect observed in Chop 2/2 mice was dependent on induction of M2 macrophages, we compared disease severity in OVA-challenged WT and Chop 2/2 mice after macrophage depletion. Macrophages in the lungs were depleted by intratracheally injecting mice with clodronate liposomes, as previously described. 20 After depletion of macrophages by clodronate liposomes, both WT and Chop 2/2 mice were then challenged with OVA, as described above. As expected, WT and Chop 2/2 mice displayed comparable disease severity, as demonstrated by histologic assays (Fig 5, A) . Consistently, the BALF samples derived from WT and Chop 2/2 mice exhibited comparable levels of inflammatory cells (Fig 5, B) . To further address this question, we examined AHR after OVA challenges. Notably, WT and Chop 2/2 mice showed comparable Rn values in response to acetylcholine (Fig 5, C) .
Next, peritoneal macrophages from WT or Chop 2/2 mice were stimulated with IL-4 for induction of M2 macrophages, and equal numbers of IL-4-induced WT or Chop 2/2 macrophages were then adoptively transferred through intratracheal injection into clodronate liposome-treated WT and Chop 2/2 mice 1 day before OVA challenges, respectively. The and WT mice after OVA challenge. A, Total number of inflammatory cells in BALF samples. B-E, Analysis of eosinophils (Fig 3, B) , lymphocytes (Fig 3, C) , macrophages (Fig 3, D) , and neutrophils (Fig 3, E) in BALF samples. F-M, Inflammatory mediators in BALF samples. Six mice were included for each study group. N, Response to acetylcholine (n 5 6-7 for each group). *P < .05, **P < .01, and ***P < .001.
adoptively transferred WT and Chop 2/2 mice had severe lung inflammation after OVA challenge. Remarkably, no detectable difference in disease severity was observed between WT and Chop 2/2 mice, as demonstrated by the comparable histologic phenotype (Fig 5, A) and a similar number of inflammatory cells in the BALF between 4 groups of mice (Fig 5, B) . Consistently, comparable Rn values were observed between the adoptively transferred WT and Chop 2/2 mice (Fig 5, C) . To confirm the above data, 1 3 10 6 WT M0 macrophages were adoptively transferred into clodronate liposome-treated Chop 2/2 mice, and the same number of Chop 2/2 M0 macrophages was adoptively transferred into clodronate liposome-treated WT mice 1 day before OVA challenge. As expected, WT mice adoptively transferred with Chop 2/2 M0 macrophages had less severe inflammatory responses after OVA challenge compared with Chop 2/2 mice adoptively transferred with WT M0 macrophages, as determined by using histologic analysis of lung sections, numbers of inflammatory cells in BALF, and Rn values (see Fig E3 in this article' s Online Repository at www.jacionline.org). Collectively, our data support that Chop deficiency-mediated protection for mice against OVA-induced allergic airway inflammation is dependent on attenuation of M2 programming in macrophages.
Chop promotes M2 programming by regulating an IL-4 positive feedback loop
To dissect the mechanisms by which Chop promotes macrophage M2 programming, we first conducted studies in peritoneal macrophages to confirm that Chop deficiency attenuates macrophage M2 programming after IL-4 stimulation. Western blot analysis revealed a significant reduction in arginase-1 expression after 6 hours of IL-4 stimulation in Chop 2/2 macrophages compared with WT macrophages (Fig 6, A) . Next, we examined the temporal expression pattern of Chop in macrophages during the course of IL-4 stimulation. Chop was expressed at low levels in macrophages before IL-4 stimulation. However, a steady increase in Chop expression was observed on IL-4 induction, and the highest expression levels were detected after 12 hours of IL-4 stimulation (Fig 6, A) .
Phosphorylated STAT6 has been reported to be critical to the optimal induction and maintenance of the M2 programming (Fig 4, D) and Ym1 (Fig 4, E) expression in the lungs. Data were collected from studies of 4 to 6 mice in each study group. *P < .05 and **P < .01.
induced by IL-4 or IL-13 stimulation. 6 Therefore we examined the effect of Chop deficiency on STAT6 phosphorylation in IL-4-stimulated peritoneal macrophages. No significant difference in total STAT6 levels was observed between WT and Chop 2/2 macrophages, and phosphorylated STAT6 was undetectable in both types of macrophages before IL-4 stimulation. However, an increase in phosphorylated STAT6 levels was detected after 0.5 hours of IL-4 stimulation, and the highest levels were noted after 1 hour of stimulation. After this time point, phosphorylated STAT6 levels underwent a steady decrease and became undetectable after 6 hours of stimulation (Fig 6, B) . A similar trend was observed in Chop 2/2 macrophages, but phosphorylated STAT6 levels were substantially reduced compared with those in WT macrophages and were undetectable as early as 1 hour after IL-4 stimulation (Fig 6, B) .
There is evidence that Tfec, a transcription factor, is a downstream target of STAT6 signaling. 21 The above results prompted us to examine the effect of Chop deficiency on Tfec expression after IL-4 stimulation in peritoneal macrophages. Remarkably, IL-4 induced a 32-fold increase in Tfec expression in WT peritoneal macrophages; however, IL-4-induced Tfec expression in Chop 2/2 macrophages was reduced by 3.2-fold compared with WT macrophages (Fig 6, C) , indicating that Chop promotes STAT6 phosphorylation to enhance Tfec transcription. The next key question is how Chop-induced Tfec promotes M2 programming. To address this question, we examined all signaling molecules relevant to the IL-4 network.
IL-4 was found to induce an 8-fold increase in expression of IL-4Ra, a gene encoding the high-affinity IL-4 receptor, 22 in WT macrophages, whereas the loss of Chop attenuated IL-4-induced IL-4Ra expression by 3-fold (Fig 6, D) . These results prompted us to hypothesize that Tfec might transcribe IL-4Ra expression. In silico analysis of the IL-4ra promoter identified 11 potential Tfec-binding sites in the IL-4ra gene (see Fig E4 in this article' s Online Repository at www.jacionline.org).
Chromatin immunoprecipitation (ChIP) was next conducted, and the resulting products were used to amplify the IL-4ra promoter regions flanking the above-indicated 11 potential Tfec binding sites. Indeed, Tfec manifested binding activity to the IL-4ra promoter in a region 2571 bp upstream of the transcriptional start site (transcriptional start site as 11; Fig 6, E) .
IL-4ra promoter reporter assays were next used to confirm these findings. A mutated IL-4ra promoter reporter (MU) was constructed, in which the Tfec-binding motif (CAGTTG) was mutated to ACGTGT, as previously described (Fig 6, F, upper  panel) . Consistently, disruption of the Tfec-binding site resulted in a 1.7-fold reduction in IL-4-induced luciferase reporter activities (Fig 6, F) . Collectively, our data support that Chop promotes macrophage M2 programming by regulating an IL-4-positive feedback loop, in which IL-4 induces Chop expression, which then promotes STAT6 signaling to transcribe Tfec expression, and Tfec next transcribes IL-4Ra expression to exacerbate M2 programming in macrophages.
Chop short hairpin RNA protects mice against OVAinduced allergic airway inflammation
To demonstrate the therapeutic potential of Chop in OVA-induced allergic airway inflammation, we constructed lentiviruses expressing a Chop short hairpin RNA (shRNA). RT-PCR analysis of lung tissues after intratracheal transduction of 8 3 10 6 lentiviruses revealed a 66% reduction of Chop expression in shRNA-transduced mice compared with that seen in mock shRNA-transduced mice (Fig 7, A) . Next, mice were subjected to repeated OVA challenges, and lentiviruses were intratracheally delivered to the lungs, as described above, on day 2 of the OVA challenge. Remarkably, Chop shRNA-transduced mice manifested reduced severity of inflammatory responses, attenuated mucus production, and improved airway remodeling compared with mock shRNA-transduced mice (Fig 7, B) . In line with these observations, the total number of inflammatory cells in the BALF was significantly reduced (7.58 6 0.73 vs 12.11 6 1.33 3 10 5 /mL, P < .05; Fig 7, C) . Specifically, the Chop shRNA-transduced mice displayed significantly lower amounts of eosinophils (3.57 6 0.36 vs 6.72 6 0.79 3 10 5 /mL, P < .05) and lymphocytes (2.14 6 0.24 vs 3.67 6 0.17 3 10 5 / mL, P < .001; Fig 7, C) . Consistently, Chop shRNAtransduced mice exhibited a marked reduction in Rn values compared with control mice in response to acetylcholine (50 mg/mL: 3.17 6 0.46 vs 5.44 6 0.42 cm H 2 O s/mL, P < .001; Fig 7, D) .
To confirm that the above-mentioned therapeutic effect of Chop shRNA was dependent on the suppression of M2 macrophage production, we conducted RT-PCR to analyze the expression of M2 markers Fizz1 and Ym1 in the lung tissues. Expression of Fizz1 and Ym1 was reduced by 2-and 1-fold, respectively. Together, our data indicate that knockdown of Chop (Fig 6, C) and IL-4Ra (Fig 6, D) . E, ChIP analysis of the IL-4ra promoter. F, Results for IL-4ra promoter luciferase reporter assays. *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 6 protects mice against OVA-induced allergic airway inflammation by suppressing the production of M2 macrophages.
Sputum CHOP
1 CD206 1 macrophage counts positively correlate with asthma severity To confirm the above-described notion in asthmatic patients, we first examined CHOP-expressing macrophages in sputum samples, followed by correlation analysis of lung function relevant to asthma severity. It was noted that cells with aberrant CHOP expression were CD14 1 macrophages, as manifested by the analysis of CHOP 1 and CD14 1 (a marker for human macrophages) cells (Fig 8, A) . Coimmunostaining of CHOP and CD206 further confirmed that those CHOP-overexpressing macrophages were characterized by an M2 phenotype (Fig 8,  B) . Next, we assessed the correlation between the number of sputum CHOP 1 CD206 1 macrophages and disease severity. Asthma severity was estimated by the ratio between FEV 1 and forced vital capacity and FEV 1 value. As expected, the number of sputum CHOP 1
CD206
1 macrophages was positively correlated with asthma severity, as manifested by the detection of a negative correlation with FEV 1 /forced vital capacity ratios (R 2 5 0.4061, P < .01; Fig 8, C) and FEV 1 values (R 2 5 0.4382, P < .01; Fig 8, D) .
DISCUSSION
In the present study we demonstrated that asthmatic patients and mice with OVA-induced allergic airway inflammation exhibit aberrant CHOP expression along with ER stress. Interestingly, CHOP was overexpressed in macrophages in both asthmatic patients and mice with OVA-induced allergic airway inflammation. Accordingly, Chop deficiency provided protection for mice against airway inflammation, remodeling, and AHR after repeated OVA challenges. Specifically, the loss of Chop protected mice from OVA-induced asthma by inhibiting the polarization of M2 macrophages in the airways. Mechanistic studies have revealed that Chop promotes macrophage M2 programming by regulating an IL-4 positive feedback loop in which IL-4 induces Chop expression, which then promotes STAT6 signaling to transcribe Tfec expression, and Tfec next transcribes IL-4Ra expression to promote macrophage M2 programming (Fig 8, E) . These results not only provide novel insights into the understanding of the pathogenesis underlying asthma but also demonstrate evidence that targeting of Chop attenuates the IL-4/STAT6/Tfec/IL-4Ra positive feedback loop to inhibit macrophage M2 programming, which can have great potential for the treatment of asthma in clinical settings. (Fig 7, E) and Ym1 (Fig 7, F) expression in the lungs. Four to 6 mice were examined in each study group. *P < .05 and **P < .01.
Emerging evidence indicates that patients with asthma are associated with the presence of ER stress, as manifested by the detection of altered BIP and CHOP expression in lung samples derived from asthmatic patients. [14] [15] [16] Studies in animals further revealed that suppression of ER stress could attenuate airway inflammation and bronchial hyperresponsiveness in a mouse model of allergic airways disease. 15, 16, 23 Consistent with these findings, analysis of induced sputum samples originated from our asthmatic patients also noted significantly higher levels of CHOP and BIP expression, and studies in lung homogenates derived from OVA-challenged asthmatic mice further demonstrated significant overexpression of Chop, phosphorylated eIF2a, Atf4, and Bip. Collectively, these data support that Chop and its related ER stress are implicated in the pathogenesis of asthma, but the exact mechanisms are yet to be elucidated.
To dissect the mechanisms by which CHOP contributes to asthma pathogenesis, we first examined CHOP expression in inflammatory cells of sputum samples derived from asthmatic patients and in BALF samples and lung tissues originating from OVA-challenged mice. In general, CHOP was hardly detectable in macrophages derived from healthy subjects and control mice.
Remarkably, significantly higher levels of CHOP were detected in sputum macrophages originating from asthmatic patients compared with those from healthy control subjects. Similarly, Chop was noted to be overexpressed in macrophages derived from OVA-induced asthmatic mice. Coimmunostaining of CHOP and CD206 confirmed that CHOP-overexpressing cells were M2 macrophages, and the number of CHOP 1
CD206
1 macrophages was associated with decreased lung function in asthmatic patients. These results support the notion that altered CHOP expression and ER stress might trigger asthma pathogenesis by promoting the generation of M2 macrophages.
Macrophages are the most abundant inflammatory cells in the airways, and macrophage activation is vital to asthma pathogenesis. Indeed, there is evidence that both M1 and M2 macrophages are important for asthma development. For example, for severe forms of asthma in aged adults, macrophages are shown to become an M1 phenotype, which produces a great amount of proinflammatory mediators, including IL-1b, to exacerbate lung injury and accelerate airway remodeling. 24 However, for the allergic form of asthma, M2 macrophages are found to be the key source of IL-4, IL-13, and Ccl17, and (Fig 8, C) and FEV 1 (Fig 8, D) in patients with asthma (n 5 18). AP, Asthmatic patients; HS, healthy subjects. ***P < .001. E, The IL-4/STAT6/Tfec/IL-4Ra positive feedback regulatory loop.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 6 suppression of the functions for M2 macrophages alleviates airway inflammation in OVA-induced asthmatic animals. 8, 9 In the present study no obvious difference in terms of IL-1b production and the percentage of CD11c
1
F4/80
1 macrophages was noted between WT and Chop 2/2 mice after repeated OVA challenges, which is consistent with our previous report that Chop deficiency does not affect macrophage M1 programming after LPS stimulation. 20 In sharp contrast, the number of M2 macrophages was significantly lower in Chop 2/2 mice compared with WT mice after OVA challenge, as demonstrated by the significantly attenuated expression of the M2 markers arginase-1, Ym1, Fizz1, CD206, and Ccl17. In line with these results, mice deficient in Chop were protected from OVA-induced allergic airway inflammation.
To address the notion that the ability of Chop deficiency to protect mice against OVA-induced allergic airway disease is dependent on the attenuation of M2 programming in macrophages, we conducted macrophage adoptive transfer studies. Clodronate liposomes were used to deplete endogenous macrophages, and IL-4-polarized WT peritoneal M2 macrophages were then adoptively transferred into clodronate liposome-treated WT and Chop 2/2 mice, followed by OVA challenge, as previously described. As expected, Chop 2/2 mice had comparable severity of allergic airway inflammation to WT mice after adoptive transfer of WT M2 macrophages. Next, WT M0 macrophages were adoptively transferred into clodronate liposome-treated Chop 2/2 mice, or Chop 2/2 M0 macrophages were adoptively transferred into clodronate liposome-treated WT mice, followed by repeated OVA challenges as described. WT mice adoptively transferred with Chop 2/2 M0 macrophages displayed less severe airway inflammation than Chop 2/2 mice transferred with WT M0 macrophages. Together, these data support that the protection resulting from Chop deficiency is dependent on its effect on the suppression of macrophage M2 programming.
The next critical issue is to dissect the pathways relevant to Chop-regulated M2 programming in macrophages. Previous studies have suggested feasible evidence that T H 2 cytokines (eg, IL-4 or IL-13) could enhance the expression of Tfec after STAT6 phosphorylation, thereby inducing expression of a subset of IL-4-responsive genes, 21 whereas IL-4Ra has a high binding affinity for IL-4 and has been noted to participate in a positive feedback loop in IL-6-induced macrophage M2 programming in adipose tissues. 25 These discoveries prompted us to hypothesize that Chop might regulate a positive feedback regulatory loop to promote M2 polarization. To address this hypothesis, we first assessed the effect of Chop deficiency on IL-4-induced STAT6 phosphorylation in macrophages. Indeed, Chop deficiency markedly inhibited IL-4-induced STAT6 phosphorylation, and consistently, the expression of the STAT6 downstream transcription factor Tfec was significantly reduced after IL-4 stimulation. It was further noted that Chop deficiency also attenuated IL-4-induced IL-4Ra expression, suggesting that IL-4Ra could be a downstream target of Tfec transcription factor. Indeed, ChIP assays demonstrated that Tfec selectively bound to the IL-4ra promoter at position -571 bp upstream of the transcriptional start site. Promoter reporter assays further confirmed that Tfec transcribed the expression of IL-4Ra after IL-4 stimulation in macrophages.
Taken together, we demonstrated experimental evidences indicating the existence of an IL-4/STAT6/Tfec/IL-4Ra positive feedback regulatory loop in macrophages, whereas Chop is likely to regulate this positive feedback regulatory loop to promote M2 programming in macrophages. In support of this notion, the number of CHOP 1 CD206 1 M2 macrophages in induced sputum has been noted to be correlated with the severity of asthma.
Previous studies have provided suggestive evidence that Chop could increase the secretion of inflammatory cytokines in a murine model of neutrophilic asthma 26 and promote epithelial apoptosis in house dust mite-induced allergic airway disease. 27 In the current report our studies in Chop 2/2 mice demonstrated additional evidence that Chop deficiency protects mice against OVA-induced allergic airway inflammation, further suggesting a great potential for Chop in the prevention and treatment of allergic airway diseases, such as asthma. Indeed, our studies using lentiviruses expressing a Chop shRNA confirmed that knockdown of Chop potently alleviated the severity of airway inflammatory responses along with attenuated mucus production and improved airway remodeling in mice after repeated OVA challenges. Nevertheless, additional follow-up studies would be necessary to fully establish the therapeutic potential of Chop in the prevention and treatment of airway inflammatory diseases in clinical settings.
In summary, we have demonstrated that altered CHOP expression along with ER stress is a characteristic feature of asthmatic patients. Mice deficient in Chop were found to be protected from OVA-induced airway inflammation and AHR. The most exciting discovery in the current report is identification of the IL-4/STAT6/Tfec/IL-4Ra positive feedback regulatory loop, which exacerbates asthma pathogenesis. Chop has been found to regulate this feedback loop to enhance M2 programming in macrophages. Together, our data indicate that targeting Chop and ER stress might represent a promising therapeutic approach for the prevention and treatment of asthma in clinical settings.
Key messages
d Mice deficient in Chop were protected from OVA-induced allergic airway inflammation as manifested by attenuated airway inflammation, remodeling, and hyperresponsiveness. 
METHODS
Human samples
Induced sputum samples were obtained from healthy volunteers (n 5 15) and asthmatic patients (n 5 18) enrolled in Tongji Hospital. All of the study subjects provided informed consent. The diagnosis of asthma was based on asthma guidelines provided by the American Thoracic Society. None of patients in the asthma group had undergone inhaled corticosteroid therapy before blood and lung function tests. E1 All studies in human subjects were conducted in accordance with the National Institutes of Health guidelines and approved by the Institutional Review Board of Tongji Hospital. The clinical characteristics of all study subjects are provided in Table E1 . 
Animals
Reagents and antibodies
Murine recombinant IL-4 was obtained from PeproTech (Rocky Hill, NJ). Antibodies against ATF4 and arginase-1 were purchased from Abcam (Cambridge, Mass), and antibodies against phosphorylated eIF2a and STAT6 were obtained from Cell Signaling Technology (Danvers, Mass). Antibodies against CHOP, BIP, glyceraldehyde-3-phosphate dehydrogenase, and phosphorylated STAT6 were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif), and Tfec antibody was obtained from Proteintech (Wuhan, China). Murine ELISA kits for IL-4, IL-5, IL-13, TGF-b1, IFN-g, IL-1b, IL-10, and Ccl17 were purchased from BD Biosciences (San Jose, Calif). All other reagents were purchased from Sigma (St Louis, Mo), unless otherwise stated.
Genotyping
The genotypes of the mice used in this study were confirmed by means of PCR. The primers use to amplify the WT allele were WT-forward 59-CAG ATC CTC ATA CCA GGC TTC C-39 and WT-reverse 59-CTC CAC CCT CTG CCA ATG TAG-39, whereas primer MU-forward 59-GCC AGG GTT TTC CCA GTC AC-39 along with the above WT-reverse primer were used to amplify the Chop null allele.
OVA-induced allergic airway inflammation model in mice
Asthma was induced in WT and Chop 2/2 mice (8-10 weeks old), as previously described, with minor modifications. E2,E3 Briefly, mice were sensitized with intraperitoneal injection of 100 mg of OVA (grade V) emulsified in 1 mg of aluminum hydroxide gel (Thermo Scientific, Rockford, Ill) in a total volume of 200 mL on days 0, 7, and 14. Mice injected with an equal volume of saline served as control animals. The sensitized mice were anesthetized with diethyl ether and intranasally challenged with 50 mL of OVA (20 mg/mL) or saline for 7 consecutive days. Chop shRNA lentiviral vectors (AAG AGA ACG AGC GGC TCA A, 8 3 10 6 infection-forming units/mouse) were injected into the anesthetized animals intratracheally 1 day after the first challenge with OVA. A mock virus (negative control shRNA) was used as a control. Mice were killed after 7 consecutive days of OVA challenge.
Analysis of airway responsiveness
Airway responsiveness to acetylcholine was assessed 24 hours after the last OVA challenge by using a computer-controlled small animal ventilator system (SCIREQ Scientific Respiratory Equipment, Montreal, Quebec, Canada), as previously described. E4 Briefly, mice were anesthetized with 10 mg/kg ketamine and 1 mg/kg xylazine, and the values for airway resistance (Rn, cm H 2 O s/mL) in response to incremental doses of acetylcholine (0.00, 6.25, 12.5, 25, and 50 mg/mL) administered by means of nebulization through the airway were recorded.
BALF preparation
BALF was collected by cannulating the trachea and lavaging the lung with 0.6 mL of sterile PBS by using previously described techniques. E5 Approximately 0.4 mL of BALF was recovered from each animal. BALF was centrifuged at 300g for 5 minutes, and the supernatants were stored at 2808C before cytokine measurement. The total cell suspension was resuspended in 1 mL of PBS. Cells were counted with a hemocytometer. Differential cell counts were measured after Diff-Quick staining.
Histologic analysis and immunostaining
The left lung was inflated with 4% neutral buffered paraformaldehyde using 25 cm of H 2 O pressure for 1 minute. The lungs were subsequently removed and placed in fresh 4% neutral buffered paraformaldehyde for 24 hours at room temperature. After embedding the tissues in paraffin, they were sliced into 5-mm sections and subjected to hematoxylin and eosin, periodic acid-Schiff, and Masson staining by using the established techniques. E6 For immunostaining, fresh frozen sections (8-mm) and smears of the induced sputum samples from asthmatic patients were prepared, as previously described. E7 The slides were coincubated with primary antibodies against F4/80 and Chop, CHOP and CD206, or CHOP and CD14, followed by probing with Alexa Fluor 5942labeled or Alexa Fluor 4882labeled secondary antibodies (Invitrogen, Carlsbad, Calif). The results were assessed by 2 pathologists by using a brightfield or fluorescent microscope in a blinded fashion.
ELISA of inflammatory cytokines
Levels of the inflammatory cytokines IL-4, IL-5, IL-13, TGF-b1, IFN-g, IL-1b, IL-10, and Ccl17 in BALF samples were measured by using commercial ELISA kits, as previously described. E8 
Western blot analysis
Lung tissues and cultured peritoneal macrophages were homogenized in lysis buffer (300 mmol/L NaCl, 50 mmol/L Tris-HCl, and 1% Triton X-100 [pH 7.5]) by using a BBX24 Bullet Blender homogenizer (Next Advance, Averill Park, NY), according to the manufacturer's protocol. Fifty micrograms of extracted proteins were separated by using 12% SDS-PAGE, and the separated proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, Calif). The membranes were first probed with indicated primary antibodies, followed by incubating with an HRP-conjugated secondary antibody. The reactive bands were visualized with an ECL Plus Western Blot Kit (Pierce, Rockford, Ill), as previously reported.
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Flow cytometric analysis
Mononuclear cells in lung tissue samples were obtained, as reported previously.
E10
Cells were then stained with anti-mouse F4/802peridinin-chlorophyll-protein complex/Cy5.5 (1:100), CD11c2 allophycocyanin (1:100), and CD2062fluorescein isothiocyanate (1:100). After washing, the cells were analyzed by means of flow cytometry, as previously described. E11 Data analysis was performed with FACS Express V3 software (De Novo Software, Glendale, Calif), as instructed.
Quantitative RT-PCR analysis
Quantitative RT-PCR analysis was conducted with SYBR Premix Ex Taq (Takara, Dalian, China), as previously described. E12 Briefly, total RNA was extracted from lung tissue or macrophages by using RNAiso plus (Takara), according to the supplier's instructions. Real-time RT-PCR was conducted to assess CD206, Fizz1, Ym1, Ccl17, Tfec, and IL-4Ra expression by using an ABI prism 7500 Sequence Detection System (Applied Biosystems, San Francisco, Calif). b-Actin or glyceraldehyde-3-phosphate dehydrogenase was used for normalization, and relative expressions for each target gene were calculated by using the 2 2DDCt approach, as reported. The primers used to amplify each target gene are listed in Table E2 .
Isolation and culture of peritoneal macrophages
Mouse peritoneal macrophages were prepared, as previously described.
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Isolated macrophages were cultured in RPMI 1640 for 30 minutes to remove nonadherent cells. Adherent cells were then cultured in RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, and recombinant IL-4 (10 ng/mL) for the indicated periods of time.
Macrophage depletion and macrophage adoptive transfer studies
Clodronate liposomes (40 mL) were administered for 2 consecutive days by means of intratracheal injection 7 days before OVA induction, and asthma severity was assessed after 7 consecutive days of OVA challenges. Adoptive transfer studies were conducted, as previously described. E14 Peritoneal macrophages derived from WT mice were stimulated with IL-4 (10 ng/mL) for 12 hours and then administered through intratracheal injection into the lungs of clodronate liposome-treated WT and Chop 2/2 mice at a density of 1 3 10 6 cells/mouse (50 mL) 1 day before challenge with OVA, as described above. The animals were then killed for further analysis.
ChIP assay and IL-4ra promoter reporter assay
ChIP assays were conducted with a ChIP assay kit (Beyotime Biotechnology, Haimen, China), as previously described. E15 Primers used in the ChIP assay are as follows: F1-59AGCCAACCCAATCCATAA39 and R1-59CCC TAGAAACCACGCAAA3'. A dual luciferase reporter system (Promega, Madison, Wis) was used for the IL-4ra promoter luciferase reporter assays in which the Tfec binding site within the IL-4ra promoter was disrupted, as previously reported. E16 
Statistical analysis
All data are presented as means 6 SEMs, and all in vitro studies were replicated a minimum of 3 times. Statistical analyses of the data were conducted with GraphPad Prism 5 software and the standard 1-way ANOVA or Dunnett multiple comparison test when appropriate. For all statistical comparisons, a P value of less than .05 was considered statistically significant.
FIG E1.
Chop is overexpressed in infiltrating macrophages in lung sections derived from OVA-challenged mice. Chop was stained in green, and F4/80 was stained in red. ***P < .001. DAPI, 49,6-diamidino-2-phenylindole.
FIG E2.
Chop selectively modulates the M2 program in macrophages. A and B, Analysis of CD206 (Fig E2, A) and Ccl17 (Fig E2, B) expression in the lung. C, Flow cytometric analysis of CD11c expression in macrophages following OVA challenges. *P < .05 and **P < .01. CD206  59-TTG GAC GGA TAG ATG GAG GG-39  59-CCA GGC AGT TGA GGA GGT TC-39  Fizz1  59-TCC CAG TGA ATA CTG ATG AGA-39  59-CCA CTC TGG ATC TCC CAA GA-39  Ym1  59-GGG CAT ACC TTT ATC CTG AG-39  59-CCA CTG AAG TCA TCC ATG TC-39  Ccl17  59-TGG CTG CCC TGC TTC TG- Gapdh, Glyceraldehyde-3-phosphate dehydrogenase.
